Evidence map›Paper›PMID 36179692›Full record

ArticleStem cell reports2022

High-content phenotyping of Parkinson's disease patient stem cell-derived midbrain dopaminergic neurons using machine learning classification.

Aurore Vuidel, Loïc Cousin, Beatrice Weykopf, Simone Haupt, Zahra Hanifehlou, Nicolas Wiest-Daesslé, Michaela Segschneider, Joohyun Lee, Yong-Jun Kwon, Michael Peitz and 5 more

Abstract read
In one paragraph

Article in Stem cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Genetic mutations in kinases: a comprehensive review on marketed inhibitors and unexplored targets in Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Aurore VuidelKsilink, Strasbourg, France.
Loïc CousinKsilink, Strasbourg, France.
Beatrice WeykopfInstitute of Reconstructive Neurobiology, University of Bonn Medical Faculty & University Hospital Bonn, Bonn, Germany; LIFE & BRAIN GmbH, Bonn, Germany.
Simone HauptLIFE & BRAIN GmbH, Bonn, Germany.
Zahra HanifehlouKsilink, Strasbourg, France.
Nicolas Wiest-DaessléKsilink, Strasbourg, France.
Michaela SegschneiderInstitute of Reconstructive Neurobiology, University of Bonn Medical Faculty & University Hospital Bonn, Bonn, Germany.
Joohyun LeeKsilink, Strasbourg, France.
Yong-Jun KwonKsilink, Strasbourg, France.
Michael PeitzInstitute of Reconstructive Neurobiology, University of Bonn Medical Faculty & University Hospital Bonn, Bonn, Germany.
Arnaud OgierKsilink, Strasbourg, France.
Laurent BrinoKsilink, Strasbourg, France.
Oliver BrüstleInstitute of Reconstructive Neurobiology, University of Bonn Medical Faculty & University Hospital Bonn, Bonn, Germany; LIFE & BRAIN GmbH, Bonn, Germany.
Peter SommerKsilink, Strasbourg, France.
Johannes H WilbertzKsilink, Strasbourg, France. Electronic address: johannes.wilbertz@ksilink.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combining multiple Parkinson's disease (PD) relevant cellular phenotypes might increase the accuracy of midbrain dopaminergic neuron (mDAN) in vitro models. We differentiated patient-derived induced pluripotent stem cells (iPSCs) with a LRRK2 G2019S mutation, isogenic control, and genetically unrelated iPSCs into mDANs. Using automated fluorescence microscopy in 384-well-plate format, we identified elevated levels of α-synuclein (αSyn) and serine 129 phosphorylation, reduced dendritic complexity, and mitochondrial dysfunction. Next, we measured additional image-based phenotypes and used machine learning (ML) to accurately classify mDANs according to their genotype. Additionally, we show that chemical compound treatments, targeting LRRK2 kinase activity or αSyn levels, are detectable when using ML classification based on multiple image-based phenotypes. We validated our approach using a second isogenic patient-derived SNCA gene triplication mDAN model which overexpresses αSyn. This phenotyping and classification strategy improves the practical exploitability of mDANs for disease modeling and the identification of novel LRRK2-associated drug targets.

Indexed as

Induced Pluripotent Stem CellsParkinson Diseasealpha-SynucleinDopaminergic NeuronsHumansInducible T-Cell Co-Stimulator ProteinLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Machine LearningMesencephalonMutationSerinealpha-SynucleinInducible T-Cell Co-Stimulator ProteinLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Serinedisease modelingiPSCLRRK2machine learningParkinson's diseaseSNCA

Identifiers

PMID36179692
PMCPMC9561636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.